AnaptysBio Announces Positive ANB032 (anti-BTLA agonist) Top-Line Phase 1 Data and Provides Pipeline Updates
April 27, 2022 16:15 ET
|
AnaptysBio, Inc.
ANB032, our wholly owned anti-BTLA agonist antibody, demonstrated favorable safety, tolerability and a rapid and sustained pharmacokinetic and pharmacodynamic profile that supports advancement...
AnaptysBio Appoints Daniel Faga As Interim Chief Executive Officer
March 21, 2022 16:15 ET
|
AnaptysBio, Inc.
Company to undergo a strategic portfolio review while continuing to execute on the development of its three wholly-owned clinical stage antibody programs SAN DIEGO, March 21, 2022 (GLOBE NEWSWIRE)...
AnaptysBio Reports Imsidolimab ACORN Phase 2 Clinical Trial Data in Moderate-to-Severe Acne
March 14, 2022 16:20 ET
|
AnaptysBio, Inc.
Imsidolimab (anti-IL-36R Ab) treatment did not demonstrate improvement over placebo in top-line primary or secondary endpointsAnaptysBio to discontinue imsidolimab clinical development in...
AnaptysBio Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Pipeline Update
March 07, 2022 08:50 ET
|
AnaptysBio, Inc.
Imsidolimab GPP GALLOP Phase 2 16-week data presented at 2021 EADV Congress and Phase 3 GPP GEMINI-1 trial initiatedTop-line data anticipated from ongoing imsidolimab ACORN Phase 2 trial in...
AnaptysBio To Present at the 40th Annual J.P. Morgan Healthcare Conference
January 05, 2022 16:05 ET
|
AnaptysBio, Inc.
SAN DIEGO, Jan. 05, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune...
AnaptysBio Announces Appointment of Daniel Faga to Board of Directors
November 29, 2021 16:05 ET
|
AnaptysBio, Inc.
SAN DIEGO, Nov. 29, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune...
AnaptysBio To Present at the 2021 Jefferies London Healthcare Conference
November 15, 2021 19:24 ET
|
AnaptysBio, Inc.
SAN DIEGO, Nov. 15, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune...
AnaptysBio Announces Positive Rosnilimab Healthy Volunteer Phase 1 Top-Line Data
November 15, 2021 09:00 ET
|
AnaptysBio, Inc.
Rosnilimab, AnaptysBio’s wholly-owned anti-PD-1 agonist antibody, demonstrated favorable safety and tolerability in single and multiple ascending dose healthy volunteer cohortsRobust pharmacokinetic...
AnaptysBio Announces Third Quarter 2021 Financial Results and Provides Pipeline Updates
November 04, 2021 16:05 ET
|
AnaptysBio, Inc.
Imsidolimab GPP GALLOP Phase 2 16-week data presented at 2021 EADV Congress and GEMINI-1 Phase 3 trial initiated subsequent to FDA end-of-Phase 2 meetingTop-line data from ongoing imsidolimab ACORN...
AnaptysBio Announces Agreement to Monetize Portion of JEMPERLI Royalties for $250 Million with Sagard
October 25, 2021 16:37 ET
|
AnaptysBio, Inc.
AnaptysBio to receive $250 million upfront cash payment from Sagard Healthcare Royalty PartnersSagard to receive AnaptysBio’s 8% royalty on annual global net sales of JEMPERLI (dostarlimab-gxly) below...